Lifeline Biotechnologies Inc (LLBO): $LLBO DD Compilation *** LLBO su...

Replies (6) Next 10 Prev Next

Send PM Follow Ignore

Followers	31
Posts	759
Boards Moderated	1
Alias Born	07/21/2010

rbd317

Re: None

Thursday, 02/19/2015 8:13:23 PM

Thursday, February 19, 2015 8:13:23 PM

$LLBO DD Compilation

***

LLBO summary

Source: http://www.otcmarkets.com/stock/LLBO/

LLBO has the status OTC Pink Current Information

The DTC Chill was removed in December, 2014

Volume increase due to the DTC Chill removed

***

LLBO – Cyrcadia Health connection

Jim Holmes (CEO) e-mail:

source: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110012246 (for educational purposes only)

Thank you for your long term support. Cyrcadia Health is licensed under LLBO's patents to complete the development, obtain regulatory clearances (CEMark for international; FDA for US), then go to market. LLBO is Cyrcadia's largest shareholder at approximately 40%.

Cyrcadia's upcoming trials are FDA directed for clearance as a Class II device. With a previous 510K on our original product, we are planning a multi-site validation trial here in the US. The timing of clearance by the FDA is never clearly defined, but we plan on filing with the FDA by mid 2015, with the intention of entering the US market by 2016. We are also filing for CE clearance for outside US release, which may be a more expedient result allowing earlier entry into countries not regulated by FDA.

So LLBO owns approximately 40% of Cyrcadia Health.

About Cyrcadia Health, Inc.

Cyrcadia Health, Inc., founded as First Warning Systems in 2008, is based in Reno, Nev. The company’s product line is a device and software service that detects breast tissue abnormalities leading to health risk assessment and management including early breast cancer identification. Three clinical trials with over 500 participants have achieved proof of concept and superior outcomes when compared to other diagnostic protocols. Cyrcadia Health is planning a final, limited clinical trial and a 510k device classification to validate the fourth generation of the product. The company is preparing to apply for a Euro CE Mark to market in the European Union and Asia Pacific markets, with FDA applications following for the US market. Visit Cyrcadia Health at http://www.cyrcadiahealth.com.

http://www.prweb.com/releases/2014/10/prweb12208686.htm

http://www.otcmarkets.com/financialReportViewer?symbol=LLBO&id=128698

Cyrcadia Health corporate website: http://cyrcadiahealth.com/technology-discussion/

Note the address in the screenshots above and below

http://www.lbti.com/#!contact/c1d94

***

LLBO – valuation

Valuation report of First Warning Systems -now Cyrcadia Health- that was done in Sept 2012:

http://quoi.info/wp-content/uploads/2012/10/executive-summary.pdf

PPS valuation: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=110016480 (for educational purposes only)

From page 2 in the report (from the link above):

1.4 SITUATION SUMMARY & ACCOMPLISHMENTS

First Warning Systems is a medical device and software company which has completed a robust proof of concept with plans to launch marketing and sales operations in early 2013. To date, FWS’ accomplishments include:

Independent Primary Market Research

1. Market research results place current value of company (pre-revenue) at $23M (US Market Only), by LSSG

2. Market research results project future value of company (post revenue) at $160M (US Market Only ), by LSSG

3. Market research results show 83% of women will use the system

4. Market research results show 60% acceptance, on average by Clinicians, 87% for high risk patients See Section detailing consultants conclusions regarding clinician acquisition rate

Accomplishments include:

1. Raised over $13M of capital investment

2. Completed three clinical trials demonstrating proof of concept

3. Achieved product accuracy up to 90% as compared to 70% of mammography

4. Demonstrated effectiveness for women under age 40 and those with dense breast tissue where mammography is not recommended because of ineffectiveness

5. Awarded four patents

6. Completed and awarded a 510 (k) for marketing clearance in the U.S. on the hardware device

7. Completed design of the fourth generation of the system, prototyping underway

8. Developing a strategic, interested go-to-market partner for EU/UK and Russian markets

9. Closing on Series A of $1,000,000 at $0.50 per share

10. Planning Series B for $5M at no less than $1.50 per share

11. Developed a strategic plan to achieve an estimated $17.01 per share by 2016

1.10 VALUATION

Current Valuation of $22.8M was independently established for the U.S. market only through primary market research conducted by Life Science Strategy Group (LSSG). With a much clearer path to revenue, the First Warning pre-market valuation from LSSG research needs updating to include EU/UK & Russian market opportunities.

First Warning Valuation (M)
2012 2016
US Market $ 23 $ 160
EU/UK Market $ 19 $ 136
Russian Market $ 14 $ 95
$ 56 $ 391

$56M x 40% (LLBO ownership) divided by 2.91B (shares outstanding of LLBO) = $.0077 PPS valuation 2012

$391M x 40% (LLBO ownership) divided by 2.91B (shares outstanding of LLBO) = $.053 PPS valuation 2016

(for educational purposes only)

***

LLBO – iTBra “exposure” by CISCO

http://blogs.cisco.com/news/internet-of-everything-targets-breast-cancer-in-detected-documentary#more-162736

Cisco is funding DETECTED, a new documentary about a medical breakthrough called iTBra, a connected bra designed to detect breast cancer in women with normal and dense breast tissue. DETECTED tells the story of thousands of hours of research, an entrepreneur who dares to dream of a new way to use the Internet of Everything to save lives, the trials of bringing experimental healthcare products to the marketplace – and much more.

The DETECTED trailer will premiere March 16 at the South By Southwest (SXSW) Festival in Austin, Texas. In the meantime, we’re excited to share the behind-the-scenes story of a powerful merger between cutting-edge science, innovative technology and the emerging wearables market. Visit our DETECTED Tumblr to follow the conversation or share your thoughts on Twitter using #DetectedMovie.